The prevalence and clinical characteristics of diabetic neuropathy in ...

More documents

Recommendations

Info

$Microsoft PowerPoint - S14-1_\300\374\274\272\277\317 [\310\243 ...$

$Microsoft PowerPoint - src.ppt [\310\243\310\257 \270\360\265\345]$

$Microsoft PowerPoint - S7-1_\300\374\277\353\260\374$

$Microsoft PowerPoint - src.ppt [\310\243\310\257 \270\360\265\345]$

$(Microsoft PowerPoint - WDXKRSAWSXRU.ppt [\310\243\310\257 ...$

EQ-5D descriptive system: 5 dimensionsNon-DPNDPNAnxiety/DepressionPain/DiscomfortUsual activitySelf-careMobility0.0 10.0 20.0 30.0 40.0 50.0Percentages of respondents reporting more than “some problem”. Each question has three levelsindicating “no problem (or 1),” “some problems (or 2),” and “severe problems (or 3),” respectively. EQ-5D, EuroQoL-5 Dimensions.EuroQol Group, Health Policy, 1990All measures are P < 0.05 between DPN and Non-DPN
Page 1 and 2: The prevalence and clinicalcharacte
Page 4 and 5: •Diabetes was associated with 2-3
Page 6 and 7: Total medical cost in patients with
Page 8 and 9: DISCLOSUREAnalysis of data from the
Page 10 and 11: Prevalence of diabetic neuropathy i
Page 12 and 13: Prevalence of DPNN = 3,339Non-DPNDP
Page 14 and 15: Clinical characteristics of DPN in
Page 16 and 17: Prevalence of DPN according to thed
Page 18 and 19: Temporal prevalence (%) of diabetic
Page 20 and 21: ORs of risk factors associated with
Page 22 and 23: Comparison of MNSI symptom distribu
Page 24 and 25: DPN: treatmentTreatment (+) Treatme
Page 26 and 27: BPI-SF (1): Pain severityNon-DPNDPN
Page 28 and 29: MOS-sleep scale• 당신솟이 필
Page 32 and 33: EQ-5D index: Korean ScoringNon-DPNP
Page 34 and 35: SummaryMore than one third of patie
Page 36 and 37: AcknowledgementFully acknowledged t

The prevalence and clinical characteristics of diabetic neuropathy in ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?